Syngeneic models

Circle Oncodesign Services

 Syngeneic Models for Drug-Host Immune System Interactions Study


Treatments targeting immune cells such as immune checkpoint modulators, bispecific antibodies or adoptive T cell transfer have now demonstrated their clinical efficacy and some of these therapies have already been approved. Anticancer vaccines via peptides, mRNA or viruses are also gaining more and more interest as alternative strategies. However, preclinical development of these therapies requires models adapted to each target and class of therapeutics. To address these needs, Oncodesign Services provides the option to use syngeneic mouse models.

Syngeneic model systems remain one of the best options to analyze physiologically relevant interactions between tumor and immune cells. Indeed, in syngeneic models, animals are grafted with tumor cells issued an animal of the same lineage. The main advantage of these models is the use of immunocompetent mice, thus allowing the study of the complex relationships between cancer and the immune system and the evaluation of immunomodulatory therapies.


Different kind of tumor models

Oncodesign Services provides a large bank of syngeneic tumor models, including breast cancer, melanoma, bladder cancer, etc .


Readouts in mouse syngeneic models

Tumor volume


Functional assays


Cytokine profiles

Examples of syngeneic mouse tumor models available at Oncodesign Services

(contact us for complete list)

Name Organ Histological Type Host rodent species
4T1 Breast Carcinoma transitional Balb/c Mouse
AY27 Bladder Carcinoma F344 Ficher Rat
C6 Brain Glioma Nude Rat
C6 Brain Glioma Wistar Rat
CT26 Colon Carcinoma Balb/c Mouse
EMT6 Breast Mammary Carcinoma Balb/c Mouse
GS-9L Brain Gliosarcoma F344 Ficher Rat
GV1A1 Brain Glioma BDIX Rat
Hepa1-6 Liver Hepatocarcinoma C57BI/6 Mouse
MBT-2 Bladder Carcinoma C3H Mouse
MBT-II Bladder Tumor Wistar Rat
NCTC 2472 Bone Sarcoma C3H Mouse
R3327H Prostate Adenocarcinoma Copenhagen Rat
Renca Kidney Carcinoma Balb/c Mouse




Explore our tumor bank

Case study: Subcutaneous CT26 model – combined immunotherapy and change in immune infiltrate

Mice were SC injected with CT26 murine colon tumor cells at D0. Mice were randomized based on tumor volume at D9 and treated IP with mAb against CTLA-4 (clone 9H10) at 5 mg/kg/inj, PD-1 (clone RMP1-14) at 10 mg/kg/inj (TWx2) or combination of both. Mice were terminated at D20 and tumor analyzed by Flow Cytometry for T cells content.


Get in touch